Johnson & Johnson reported a strong first quarter with robust revenue growth driven by its Innovative Medicine and MedTech segments. The company demonstrated solid operational execution, though net earnings saw a significant decline due to a large one-time gain in the prior year's quarter.
Worldwide sales increased 9.9% to $24.1 billion, driven by strong performance in both Innovative Medicine and MedTech segments.
positiveInnovative Medicine segment sales grew 11.2% operationally to $15.4 billion, with strong contributions from Oncology and Neuroscience.
positiveMedTech segment sales increased 7.7% operationally to $8.6 billion, with growth across Cardiovascular, Surgery, Vision, and Orthopaedics.
positiveOperational sales growth of 6.4% globally, indicating strong underlying business performance.
positiveReported Net Earnings decreased by 52.4% to $5.2 billion, primarily due to a significant one-time gain in the prior year's quarter related to 'Other (income) expense, net'.
negativeDiluted EPS decreased by 52.9% to $2.14, reflecting the decline in net earnings.
negativeAdjusted Net Earnings decreased by 1.4% to $6.6 billion, and Adjusted Diluted EPS decreased by 2.5% to $2.70, indicating some pressure on profitability even after excluding special items.
attentionImbruvica sales declined 39.1% in the US and 6.9% worldwide, indicating a significant impact from competition or patent expirations.
attentionStelara sales decreased 77.6% in the US and 59.7% worldwide, likely due to biosimilar competition.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total | CC |
|---|---|---|---|---|---|
Innovative Medicine | N/A | — | — | — | +7.4% |
MedTech | N/A | — | — | — | +4.6% |
| Total Revenue | $0.00M | — | — | 100.0% | — |
Segment performance shows business unit health and growth drivers. Constant currency (CC) removes FX impact for like-for-like comparison.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Strong first-quarter performance driven by robust growth in Innovative Medicine and MedTech.
Operational sales growth of 6.4% reflects strong underlying business momentum.
Continued focus on innovation and expanding market access for key products.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.